Live Webinar

Please make note of the activity timeframe in your Time Zone:
3:00 to 4:00pm PT | 4:00 to 5:00pm MT | 5:00 to 6:00pm CT | 6:00 to 7:00pm ET

Clinicians may have gaps in knowledge regarding the evolving evidence and clinical criteria for incorporating adjuvant CDK 4/6 inhibitors into treatment of HR-positive/HER2-negative early breast cancer. Clinicians need greater clarity regarding who should receive therapy, which agent is most appropriate, how therapy should be integrated with endocrine treatment, and how toxicities should be proactively managed to optimize adherence and outcomes. Clinicians need increased knowledge and confidence in identifying appropriate patients for adjuvant CDK4/6 therapy and translating rapidly evolving evidence into individualized treatment decisions that balance recurrence risk, clinical benefit, toxicity, and patient preferences. 

There is rapidly evolving evidence supporting adjuvant CDK4/6 inhibitors and consistent translation of that evidence into individualized clinical practice. Currently, use of adjuvant CDK4/6 inhibitors may vary across clinical practice, with inconsistent identification of patients at sufficiently high risk of recurrence to benefit from treatment. Clinicians may also vary in how they weigh absolute benefit against adverse effects, treatment duration, monitoring requirements, cost, and patient preferences.  Ideally, clinicians consistently assess recurrence risk and apply current evidence and guideline recommendations to identify appropriate candidates for adjuvant CDK4/6 inhibition. It is imperative for clinicians to stay abreast of appropriate patient selection, recurrence-risk assessment, differences between available CDK4/6 inhibitors, treatment duration, toxicity management, and integration with endocrine therapy.